ºù«Ӱҵ

I joined SCHARR as a staff member after completing my PhD here, where I specialised in treatment sequences in health economic evaluations and the incorporation of advanced causal inference methods. My research focuses on applying these techniques—such as Target Trial Emulation and g-methods—to generate real-world evidence on the comparative effectiveness of treatment sequences using secondary databases. My research addresses the challenges in evaluating treatment sequences within HTA due to the lack of clinical evidence, as trials typically do not compare treatment sequences. Importantly, merging evidence from different treatment lines of trials requires making population exchangeability assumptions, which may not always hold.

Prior to my PhD, I obtained a BSc and an MSc in Pharmacy/Clinical Pharmacy, during which I developed a cost-effectiveness model that informed the national reimbursement of a pharmacist-led anticoagulation service in Taiwan. I then worked in an academic role with consultancy responsibilities, supporting local HTA submissions for pharmaceutical companies by adapting oncology economic models and generating local evidence using national claims data. Alongside this core responsibility, I contributed to the construction of the Taiwan EQ-5D-5L tariff model and healthcare utilisation and pharmacoepidemiology studies using Taiwan national health insurance claims and US NHIS survey data. Additionally, I worked as a pharmacist from time to time.